JPMorgan Chase & Co. Cuts Stake in Imperva Inc (IMPV)
JPMorgan Chase & Co. lowered its position in shares of Imperva Inc (NYSE:IMPV) by 10.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,453,416 shares of the software maker’s stock after selling 174,582 shares during the period. JPMorgan Chase & Co. owned about 4.30% of Imperva worth $69,547,000 at the end of the most recent quarter.
Several other institutional investors have also recently made changes to their positions in the company. Comerica Bank increased its stake in shares of Imperva by 0.8% during the second quarter. Comerica Bank now owns 19,707 shares of the software maker’s stock valued at $978,000 after buying an additional 157 shares during the period. Aperio Group LLC increased its stake in shares of Imperva by 8.1% during the second quarter. Aperio Group LLC now owns 7,114 shares of the software maker’s stock valued at $340,000 after buying an additional 531 shares during the period. Smith Asset Management Group LP increased its stake in shares of Imperva by 0.8% during the second quarter. Smith Asset Management Group LP now owns 81,295 shares of the software maker’s stock valued at $3,890,000 after buying an additional 610 shares during the period. US Bancorp DE increased its stake in shares of Imperva by 11.7% during the second quarter. US Bancorp DE now owns 6,016 shares of the software maker’s stock valued at $287,000 after buying an additional 630 shares during the period. Finally, Cambridge Trust Co. increased its stake in shares of Imperva by 4.7% during the second quarter. Cambridge Trust Co. now owns 23,839 shares of the software maker’s stock valued at $1,141,000 after buying an additional 1,081 shares during the period. Hedge funds and other institutional investors own 92.72% of the company’s stock.
In other news, Director Anthony J. Bettencourt sold 99,598 shares of the firm’s stock in a transaction that occurred on Thursday, August 24th. The stock was sold at an average price of $43.59, for a total value of $4,341,476.82. Following the completion of the sale, the director now directly owns 99,598 shares of the company’s stock, valued at approximately $4,341,476.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 2.20% of the stock is owned by company insiders.
Shares of Imperva Inc (NYSE IMPV) opened at 45.75 on Tuesday. The firm’s market cap is $1.55 billion. The company’s 50 day moving average price is $44.76 and its 200-day moving average price is $45.48. Imperva Inc has a 12-month low of $34.40 and a 12-month high of $57.24.
Imperva (NYSE:IMPV) last posted its quarterly earnings data on Thursday, July 27th. The software maker reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by $0.15. Imperva had a negative return on equity of 5.00% and a negative net margin of 4.69%. The company had revenue of $74.44 million for the quarter, compared to analyst estimates of $74.30 million. During the same period in the previous year, the business posted ($0.23) earnings per share. The firm’s revenue was up 28.6% compared to the same quarter last year. On average, equities research analysts anticipate that Imperva Inc will post $0.81 EPS for the current year.
Several equities analysts have recently commented on the company. BidaskClub upgraded Imperva from a “sell” rating to a “hold” rating in a research note on Tuesday. Piper Jaffray Companies set a $58.00 price objective on Imperva and gave the company a “buy” rating in a research report on Monday, August 28th. Evercore ISI set a $56.00 price objective on Imperva and gave the company a “buy” rating in a research report on Thursday, August 10th. Zacks Investment Research raised Imperva from a “hold” rating to a “strong-buy” rating and set a $52.00 price objective on the stock in a research report on Wednesday, August 2nd. Finally, Monness Crespi & Hardt raised their price objective on Imperva from $55.00 to $57.00 and gave the company a “buy” rating in a research report on Friday, July 28th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $52.81.
Imperva Company Profile
Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company is engaged in the development, marketing, sales, service and support of cyber-security solutions. The Company’s products include its Imperva SecureSphere Paltform, Imperva CounterBreach and Imperva Camouflage for enterprise data centers, and Imperva Incapsula offering for cloud-based security services.
Receive News & Ratings for Imperva Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.